MA38323B1 - Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale - Google Patents

Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale

Info

Publication number
MA38323B1
MA38323B1 MA38323A MA38323A MA38323B1 MA 38323 B1 MA38323 B1 MA 38323B1 MA 38323 A MA38323 A MA 38323A MA 38323 A MA38323 A MA 38323A MA 38323 B1 MA38323 B1 MA 38323B1
Authority
MA
Morocco
Prior art keywords
amelioration
prevention
treatment
viral disease
pyrimidone derivatives
Prior art date
Application number
MA38323A
Other languages
English (en)
Other versions
MA38323A1 (fr
Inventor
Zhuming Zhang
Achyutharao Sidduri
Andrea Wolkerstorfer
Oliver Szolar
Norbert Handler
Helmut Buschmann
Stephen Cusack
Mark Smith
Sung-Sau So
Ronald Charles Hawley
Original Assignee
Hoffmann La Roche
Savira Pharmaceuticals Gmbh
European Molecular Biology Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50070507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38323(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Savira Pharmaceuticals Gmbh, European Molecular Biology Laboratory filed Critical Hoffmann La Roche
Publication of MA38323A1 publication Critical patent/MA38323A1/fr
Publication of MA38323B1 publication Critical patent/MA38323B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne un composé de formule générale (i), éventuellement sous la forme d'un sel, solvate, polymorphe, comédicament, cocristal, promédicament, tautomère, racémique, énantiomère ou diastéréoisomère pharmaceutiquement acceptable ou d'un mélange de ceux-ci, qui sont utiles dans le traitement, l'amélioration ou la prévention d'une maladie virale. De plus, l'invention concerne des polythérapies spécifiques.
MA38323A 2013-01-08 2014-01-07 Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale MA38323B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750017P 2013-01-08 2013-01-08
PCT/EP2014/050165 WO2014108406A1 (fr) 2013-01-08 2014-01-07 Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale

Publications (2)

Publication Number Publication Date
MA38323A1 MA38323A1 (fr) 2017-02-28
MA38323B1 true MA38323B1 (fr) 2018-05-31

Family

ID=50070507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38323A MA38323B1 (fr) 2013-01-08 2014-01-07 Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale

Country Status (21)

Country Link
US (1) US9045486B2 (fr)
EP (1) EP2943495B1 (fr)
JP (1) JP2016518305A (fr)
KR (1) KR20150103285A (fr)
CN (1) CN104918942A (fr)
AR (1) AR094378A1 (fr)
AU (1) AU2014204889A1 (fr)
BR (1) BR112015012693A2 (fr)
CA (1) CA2894642A1 (fr)
CL (1) CL2015001916A1 (fr)
CR (1) CR20150337A (fr)
EA (1) EA201591291A1 (fr)
HK (1) HK1211286A1 (fr)
IL (1) IL239656A0 (fr)
MA (1) MA38323B1 (fr)
MX (1) MX2015008293A (fr)
PE (1) PE20151722A1 (fr)
PH (1) PH12015501517A1 (fr)
SG (1) SG11201503946UA (fr)
TW (1) TW201443053A (fr)
WO (1) WO2014108406A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
IL239682B (en) 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
KR102323515B1 (ko) 2013-09-12 2021-11-05 얀센 바이오파마, 인코퍼레이트. 아자-피리돈 화합물 및 이의 용도
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
EA036776B1 (ru) 2015-03-11 2020-12-21 Янссен Байофарма, Инк. Соединения азапиридона и способы их применения
DK4219508T3 (da) 2015-04-28 2024-08-05 Shionogi & Co Substitueret polycyklisk pyridonderivat og prodrug deraf
US9988390B2 (en) 2015-10-30 2018-06-05 F. Hoffmann-La Roche Ag Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6323860B2 (ja) 2015-12-15 2018-05-16 塩野義製薬株式会社 キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬
WO2017109088A1 (fr) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Dérivés pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
WO2017158147A1 (fr) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Dérivés de pyrimidone et leur utilisation pour le traitement, la prévention ou l'atténuation des symptômes d'une maladie virale
WO2017158151A1 (fr) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Dérivés de pyrimidone et leur utilisation dans le traitement, le soulagement ou la prévention d'une maladie virale
JP6961963B2 (ja) * 2016-04-01 2021-11-05 三菱ケミカル株式会社 フルフラールの製造方法
EP3458455B1 (fr) * 2016-05-20 2021-06-16 F. Hoffmann-La Roche AG Nouveaux composés de pyrazine ayant un coupleur d'oxygène, de soufre et d'azote pour le traitement de maladies infectieuses
WO2017207983A1 (fr) 2016-05-31 2017-12-07 Kalvista Pharmaceuticals Limited Dérivés de pyrazole en tant qu'inhibiteurs de la kallicréine plasmatique
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
AU2017310774B2 (en) 2016-08-10 2023-01-19 Shionogi & Co., Ltd. Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
JP7078722B2 (ja) 2017-11-29 2022-05-31 カルビスタ・ファーマシューティカルズ・リミテッド 血漿カリクレイン阻害剤を含む剤形
EA202091696A1 (ru) 2018-02-28 2021-01-27 Новартис Аг ПРОИЗВОДНЫЕ 10-(ДИ(ФЕНИЛ)МЕТИЛ)-4-ГИДРОКСИ-8,9,9a,10-ТЕТРАГИДРО-7H-ПИРРОЛО[1',2':4,5]ПИРАЗИНО[1,2-b]ПИРИДАЗИН-3,5-ДИОНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ РЕПЛИКАЦИИ ОРТОМИКСОВИРУСА ДЛЯ ЛЕЧЕНИЯ ГРИППА
WO2021028645A1 (fr) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Inhibiteurs de la kallicréine plasmatique
US20240228495A1 (en) * 2020-03-25 2024-07-11 Sri International Tricyclic Inhibitors of Influenza Virus Endonuclease
EP4074317A1 (fr) 2021-04-14 2022-10-19 Bayer AG Dérivés de phosphore en tant que nouveaux inhibiteurs de sos1
WO2024061300A1 (fr) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibiteurs de trex1 et utilisations associées
AU2023362450A1 (en) 2022-10-19 2025-05-29 Astrazeneca Ab 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3 cr1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
CA2557926A1 (fr) 2004-03-09 2005-09-22 Monica Donghi Inhibiteurs de l'integrase du vih
CN101014572B (zh) 2004-09-15 2011-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物
EP1888581A2 (fr) 2005-05-16 2008-02-20 Gilead Sciences, Inc. Hiv-composes inhibant l'integrase
US20080076740A1 (en) * 2005-07-27 2008-03-27 Gilead Sciences, Inc. Antiviral compounds
WO2010110231A1 (fr) 2009-03-26 2010-09-30 塩野義製薬株式会社 Dérivé de 3-hydroxy-4-pyridone substitué
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
DK2444400T3 (en) 2009-06-15 2018-06-18 Shionogi & Co SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE
WO2011000566A2 (fr) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Composés et compositions pharmaceutiques pour le traitement de d’infections virales à arn simple brin, sens négatif
CA2812363C (fr) 2010-09-24 2019-04-02 Shionogi & Co., Ltd. Promedicament derive de carbamoylpyridone polycyclique substituee

Also Published As

Publication number Publication date
EP2943495B1 (fr) 2016-12-28
PE20151722A1 (es) 2015-11-19
JP2016518305A (ja) 2016-06-23
MX2015008293A (es) 2016-06-02
EA201591291A1 (ru) 2015-12-30
IL239656A0 (en) 2015-08-31
EP2943495A1 (fr) 2015-11-18
PH12015501517A1 (en) 2015-11-09
AR094378A1 (es) 2015-07-29
CA2894642A1 (fr) 2014-07-17
WO2014108406A1 (fr) 2014-07-17
HK1211286A1 (en) 2016-05-20
KR20150103285A (ko) 2015-09-09
CR20150337A (es) 2015-11-02
MA38323A1 (fr) 2017-02-28
US20140194431A1 (en) 2014-07-10
AU2014204889A1 (en) 2015-06-11
CN104918942A (zh) 2015-09-16
CL2015001916A1 (es) 2016-01-22
BR112015012693A2 (pt) 2017-07-11
HK1212686A1 (en) 2016-06-17
TW201443053A (zh) 2014-11-16
US9045486B2 (en) 2015-06-02
SG11201503946UA (en) 2015-09-29

Similar Documents

Publication Publication Date Title
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
MX2014014109A (es) Derivados de 7-oxo-4,7-dihidro-pirazolo[1,5-a]pirimidina que son utiles en el tratamiento, mejora o prevencion de una enfermedad viral.
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
HK1211289A1 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
PH12014500326B1 (en) Heterocyclic derivative and pharmaceutical drug
JP2019524883A5 (fr)
MA37405A1 (fr) Composés hétérocyclyle
WO2008094909A3 (fr) Composés de quinazolinone et de pyrimidinone fusionnés et leur utilisation dans le traitement de maladies ou d'affections induites par les canaux sodiques
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
EA201491283A1 (ru) Ингибитор регулирующей апоптотические сигналы киназы
PH12016500359A1 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
MA38138A1 (fr) Dérivés inédits de quinolone
MX2009003874A (es) Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
EA200900178A1 (ru) Конденсированные гетероциклические производные и их применение
MX342176B (es) Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
TN2017000158A1 (en) Carbazole derivatives
MX2014003803A (es) Derivados de acido heteroarilo hidroxamico y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MA39983A (fr) Dérivés de carboxamide
EA201591649A1 (ru) Составы с органическими соединениями
JOP20200263B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين d1
WO2008109856A3 (fr) Procédés de traitement de maladies ou d'affections associées aux canaux à sodium au moyen de composés de type diazépinone.